DIA-HEMOSTASIS IMMUNOENZYME TEST SYSTEM FOR SIMULTANEOUS QUANTIFICATION OF FIBRINOGEN, SOLUBLE FIBRIN, AND D-DIMER IN HUMAN BLOOD PLASMA



Areas of Application

This integral test system can be used for simultaneous quantification of fibrinogen, soluble fibrin, and d-dimer in human blood plasma in order to make comprehensive diagnosis of the hemostasis system, to detect or to prevent the thrombosis risk under various pathologies at the early stages of disease, to monitor antithrombotic and fibrinolytic therapy in cardiology, surgical and obstetric practice, combustiology, oncology, and endocrinology

Stage of Development. Suggestion for Commercialization

IRL8, TRL8
Seeking partners for mass production and marketing

Specification

High sensitivity (0.5 \pm 0.1 μ g/ml); high specificity (98%); time of analysis: 3 hours; automated parameter quantification; long-term storage life. The test system has been trialed in leading clinics of Ukraine and has shown positive results

Advantages

There are no analogs. As compared with the known test systems based on expensive commercial antibodies, this test system uses highly specific monoclonal antibodies of our own production

IPR Protection

IPR3

Contact Information

Denys V. Kolybo, Palladin Institute of Biochemistry of the NAS of Ukraine; +38 044 234 81 33, e-mail: kolibo@biochem.kiev.ua